NeuroSearch cardiovascular news

NeuroSearch will spin out newco Acesion Pharma ApS to focus on developing products to treat atrial fibrillation (AF) based on NeuroSearch's sodium and potassium ion channels program. Acesion will receive an option to license new and existing compounds developed within the program.

If the option is exercised, NeuroSearch would receive an upfront minority ownership in Acesion. NeuroSearch would also be eligible for milestone payments of up to €30 million ($39.9 million) in cash as well as additional ownership of the company, plus royalties. ...